Elevated Aβ aggregates in feces from Alzheimer's disease patients: a proof-of-concept study

被引：1

作者：

Pils, Marlene ^{[1
,2
]}

Dybala, Alexandra ^{[3
]}

Schaffrath, Anja ^{[1
]}

Rehn, Fabian ^{[1
,2
]}

Kutzsche, Janine ^{[1
]}

Bloemeke, Lara ^{[1
]}

Tusche, Markus ^{[1
]}

Oezduezenciler, Pelin ^{[1
]}

Bujnicki, Tuyen ^{[1
]}

Kraemer-Schulien, Victoria ^{[1
]}

Gramespacher, Hannes ^{[4
]}

Schmieschek, Maximilian H. T. ^{[4
]}

Barbe, Michael T. ^{[4
]}

Onur, Oezguer A. ^{[4
,5
]}

Fink, Gereon R. ^{[4
,5
]}

Tamguney, Gultekin ^{[1
,3
]}

Bannach, Oliver ^{[1
,2
]}

Willbold, Dieter ^{[1
,2
,3
]}

机构：

[1] Forschungszentrum Julich, Inst Biol Informat Proc, Struct Biochem IBI 7, D-52428 Julich, Germany

[2] attyloid GmbH, D-40225 Dusseldorf, Germany

[3] Heinrich Heine Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany

[4] Univ Cologne, Univ Hosp Cologne, Fac Med, Dept Neurol, D-50937 Cologne, Germany

[5] Res Ctr Julich, Inst Neurosci & Med INM 3, Cognit Neurosci, D-52428 Julich, Germany

来源：

ALZHEIMERS RESEARCH & THERAPY | 2024年 / 16卷 / 01期

关键词：

Amyloidosis; A beta oligomer quantitation; sFIDA; Brain-gut-microbiota axis; Leaky gut; Fecal/stool samples; Clearance; MILD COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; GUT-MICROBIOTA; DIAGNOSIS; BRAIN;

D O I：

10.1186/s13195-024-01597-3

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

BackgroundMisfolding and aggregation of amyloid beta (A beta), along with neurofibrillary tangles consisting of aggregated Tau species, are pathological hallmarks of Alzheimer's disease (AD) onset and progression. In this study, we hypothesized the clearance of A beta aggregates from the brain and body into the gut.MethodsTo investigate this, we used surface-based fluorescence intensity distribution analysis (sFIDA) to determine the A beta aggregate concentrations in feces from 26 AD patients and 31 healthy controls (HC).ResultsA beta aggregates were detectable in human feces and their concentrations were elevated in AD patients compared to HC (specificity 90.3%, sensitivity 53.8%).ConclusionThus, fecal A beta aggregates constitute a non-invasive biomarker candidate for diagnosing AD. Whether digestion-resistant A beta aggregates in feces are secreted via the liver and bile or directly from the enteric neuronal system remains to be elucidated.

引用

页数：15

共 50 条

[1] Plasma lipoproteome in Alzheimer’s disease: a proof-of-concept study
Danni Li
Fangying Huang
Yingchun Zhao
Peter W. Villata
Timothy J. Griffin
Lin Zhang
Ling Li
Fang Yu
Clinical Proteomics, 2018, 15
[2] Plasma lipoproteome in Alzheimer's disease: a proof-of-concept study
Li, Danni
Huang, Fangying
Zhao, Yingchun
Villata, Peter W.
Griffin, Timothy J.
Zhang, Lin
Li, Ling
Yu, Fang
CLINICAL PROTEOMICS, 2018, 15
[3] Functional imaging of hippocampal dysfunction among persons with Alzheimer's disease: a proof-of-concept study
Arciniegas, David B.
Tregellas, Jason R.
Rojas, Donald C.
Hewitt, Burlleen
Anderson, C. Alan
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 779 - 783
[4] Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease
Koronyo, Yosef
Biggs, David
Barron, Ernesto
Boyer, David S.
Pearlman, Joel A.
Au, William J.
Kile, Shawn J.
Blanco, Austin
Fuchs, Dieu-Trang
Ashfaq, Adeel
Frautschy, Sally
Cole, Gregory M.
Miller, Carol A.
Hinton, David R.
Verdooner, Steven R.
Black, Keith L.
Koronyo-Hamaoui, Maya
JCI INSIGHT, 2017, 2 (16)
[5] Webcam-Based Eye-Tracking of Attentional Biases in Alzheimer's Disease: A Proof-Of-Concept Study
Greenaway, Anne-Marie
Hwang, Faustina
Nasuto, Slawomir
Ho, Aileen
CLINICAL GERONTOLOGIST, 2024, 47 (01) : 98 - 109
[6] Using Biomarkers to Predict Memantine Effects in Alzheimer's Disease: A Proposal and Proof-Of-Concept Demonstration
Swerdlow, Neal R.
Kotz, Juliana E.
Joshi, Yash B.
Talledo, Jo
Sprock, Joyce
Molina, Juan L.
Huisa, Branko
Huege, Steven F.
Romero, Jairo Alberto
Walsh, Michael J.
Delano-Wood, Lisa
Light, Gregory A.
JOURNAL OF ALZHEIMERS DISEASE, 2021, 84 (04) : 1431 - 1438
[7] Gastrointestinal Motility and Response to Levodopa in Parkinson's Disease: A Proof-of-Concept Study
Safarpour, Delaram
Brumbach, Barbara H.
Arena, Monica
Quinn, Joseph
Diamond, Sarah
Nutt, Jay G.
Pfeiffer, RonaldF.
MOVEMENT DISORDERS, 2022, 37 (10) : 2153 - 2158
[8] Elephants, Parkinson's Disease, and Proof-of-Concept Clinical Trials
Cedarbaum, Jesse M.
MOVEMENT DISORDERS, 2018, 33 (05) : 697 - 700
[9] Classification of Patients with Alzheimer's Disease and Dementia with Lewy Bodies using Resting EEG Selected Features at Sensor and Source Levels: A Proof-of-Concept Study
San-Martin, Rodrigo
Fraga, Francisco J.
Del Percio, Claudio
Lizio, Roberta
Noce, Giuseppe
Nobili, Flavio
Arnaldi, Dario
D'Antonio, Fabrizia
De Lena, Carlo
Guntekin, Bahar
Hanoglu, Lutfu
Taylor, John Paul
McKeith, Ian
Stocchi, Fabrizio
Ferri, Raffaele
Onofrj, Marco
Lopez, Susanna
Bonanni, Laura
Babiloni, Claudio
CURRENT ALZHEIMER RESEARCH, 2021, 18 (12) : 956 - 969
[10] Cannabidiol Treatment Improves Glucose Metabolism and Memory in Streptozotocin-Induced Alzheimer's Disease Rat Model: A Proof-of-Concept Study
de Paula Faria, Daniele
Estessi de Souza, Larissa
Duran, Fabio Luis de Souza
Buchpiguel, Carlos Alberto
Britto, Luiz Roberto
Crippa, Jose Alexandre de Souza
Busatto Filho, Geraldo
Real, Caroline Cristiano
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (03)

← 1 2 3 4 5 →